Skip Nav Destination
Issues
Journal Name Change
Vol. 1-36 (1978-2013) were published under the journal's former title Onkologie.
Oncology Research and Treatment 2024, Vol. 47, No. 12
Editorial
ONKOPEDIA Guideline Updates “in a Nutshell” for the Readers of Oncology Research and Treatment
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 587–588.
https://doi.org/10.1159/000542515
Research Article
Evaluating the Impact of Age and G8 Assessment on Definitive Treatment Strategies in Elderly Patients with Local Advanced Esophageal Carcinoma
Subject Area:
Oncology
Berna Akkus Yildirim; Sedef Gokhan Acikgoz; Mustafa Halil Akboru; Emre Uysal; Baver Tütün; Necla Gurdal; Yilmaz Tezcan
Oncol Res Treat (2024) 47 (12): 590–600.
https://doi.org/10.1159/000542017
Review Article
A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 602–608.
https://doi.org/10.1159/000541520
Guidelines
Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer
Subject Area:
Oncology
Ralf-Dieter Hofheinz; Dirk Arnold; Markus Borner; Wolfgang Eisterer; Gunnar Folprecht; Michael Ghadimi; Ullrich Graeven; Birgit Grünberger; Holger Hebart; Susanna Hegewisch-Becker; Volker Heinemann; Ron Pritzkuleit; Claus Rödel; Holger Rumpold; Tanja Trarbach; Georg Maschmeyer; Bernhard Wörmann
Oncol Res Treat (2024) 47 (12): 610–614.
https://doi.org/10.1159/000541376
Novel Insights from Clinical Practice
EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
Subject Area:
Oncology
Maria F. Martínez-Hernandez; Luis Lara-Mejía; Carlos Izquierdo-Tolosa; Luis Cabrera-Miranda; Oscar Arrieta
Oncol Res Treat (2024) 47 (12): 616–622.
https://doi.org/10.1159/000541496
Acknowledgement to Reviewers
Acknowledgement to Reviewers
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 624.
https://doi.org/10.1159/000542173
PharmaForum
Vorteile des MAIA-Regimes bei Hochrisikozytogenetik
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 626–627.
https://doi.org/10.1159/000542741
Epcoritamab: Indikationserweiterung für das FL
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 628–629.
https://doi.org/10.1159/000542690
Ivosidenib: Zielgerichtete Therapieoption bei IDH1-Mutationen
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 630–631.
https://doi.org/10.1159/000542742
Pharma News
PharmaNews
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 633–640.
https://doi.org/10.1159/000542688
Society Bulletins
Society Bulletins
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): 642–648.
https://doi.org/10.1159/000542564
Contents Vol. 47, 2024
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (12): I.
https://doi.org/10.1159/000542794
